| 1. |
- Longinetti, E., et al.
(författare)
-
COVID-19 clinical outcomes and DMT of MS patients and population-based controls
- 2022
-
Ingår i: Annals of Clinical and Translational Neurology. - : Wiley. - 2328-9503. ; 9:9, s. 1449-1458
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To estimate risks for all-cause mortality and for severe COVID-19 in multiple sclerosis patients and across relapsing-remitting multiple sclerosis patients exposed to disease-modifying therapies. Methods: We conducted a Swedish nationwide population-based multi-register linkage cohort study and followed all multiple sclerosis patients (n = 17,692 in March 2020), individually age-, sex-, and region-matched to five population-based controls (n = 86,176 in March 2020) during March 2020-June 2021. We compared annual all-cause mortality within and across cohorts, and assessed incidence rates and relative risks for hospitalization, intensive care admission, and death due to COVID-19 in relation to disease-modifying therapy use, using Cox regression. Results: Absolute all-cause mortality among multiple sclerosis patients was higher from March to December 2020 than in previous years, but relative risks versus the population-based controls were similar to preceding years. Incidence rates of hospitalization, intensive care admission, and death due to COVID-19 remained in line with those for all-cause hospitalization, intensive care admission, and mortality. Among relapsing-remitting patients on rituximab, trends for differences in risk of hospitalization due to COVID-19 remained in the demographics-, socioeconomic status-, comorbidity-, and multiple sclerosis severity-adjusted model. Interpretation: Risks of severe COVID-19-related outcomes were increased among multiple sclerosis patients as a whole compared to population controls, but risk increases were also seen for non-COVID-19 hospitalization, intensive care admission, and mortality, and did not significantly differ during the pandemic compared to pre-pandemic years. The risk conveyed by disease-modifying therapies was smaller than previously assumed, likely as a consequence of the possibility to better control for confounders.
|
|
| 2. |
- Azad, A.K., Eriksson, S.-G., Mellergård, A. Ivanov, S.A., Eriksen, J. Rundlöf, H.
(författare)
-
A study on the nuclear and magnetic structure of the double perovskite A2FeWO6 (A = Sr, Ba) by neutron diffraction and reverse Monte Carlo modeling
- 2002
-
Ingår i: Materials Research Bulletin. ; 37, s. 1797-1813
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
- Azad, A.K., Mellergård, A., Eriksson, S.-G., Ivanov, S.A., Eriksen, J. and Rundlöf, H.
(författare)
-
Preparation, crystal and magnetic structure of the double perovskite Ba2FeWo6
- 2002
-
Ingår i: Applied Physics. ; A74, s. 763-765
-
Tidskriftsartikel (refereegranskat)
|
|
| 4. |
|
|
| 5. |
- Longinetti, E., et al.
(författare)
-
SARS-COV2 exposure rates and serological response of people living with MS
- 2022
-
Ingår i: Multiple Sclerosis Journal. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 28:Suppl. 3, s. 515-516
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Introduction: Some multiple sclerosis (MS) disease-modifying therapies (DMTs) are associated with blunted humoral vaccination responses, but relevance for SARS-CoV-2 infection is unclear.Objectives: To determine SARS-CoV-2 exposure rates and formation of antibody memory among participants of the COMparison Between All immunoTherapies for MS (COMBAT-MS; NCT03193866) and the Immunomodulation and MS Epidemiology (IMSE) studies.Aim: To determine SARS-CoV2 serological response of people living with MS (pwMS).Methods: Using a multiplex bead-based assay we determined SARS-CoV-2 spike and nucleocapsid antibody levels in 3,723 pwMS in paired serum samples (n=7,157) donated prior (Results: Specificity and sensitivity of the assay for SARS-CoV-2 was 100% and 99.7%, respectively. The proportion of positive samples for SARS-CoV-2 differed moderately across DMTs with the highest values among cladribine-treated (7.4%) and the lowest number among rituximab-treated pwMS (3.9%). Similarly, the proportion of positive cases not reported in the Swedish MS registry varied from 100% for cladribine to 33.3% among untreated pwMS. Comparing levels of antibodies titers showed that levels were lower among those treated with rituximab or fingolimod vs interferon treated pwMS. Point estimates indicated a similar trend comparing rituximab or fingolimod vs untreated pwMS.Conclusions: Overall rates of SARS-CoV-2 antibody positivity after the first COVID-19 wave differed only moderately across DMTs, while antibody levels were lower with rituximab or fingolimod compared to interferon-treated pwMS. This indicates quantitative rather than qualitative differences in the humoral response to infection.
|
|
| 6. |
- Ahi, A, et al.
(författare)
-
Local and average atomic order of ion-conducting Bi0.775La0.225O1.5 studied by neutron scattering and reverse Monte Carlo simulations
- 2006
-
Ingår i: Solid State Ionics. - 0167-2738. ; 177, s. 289-297
-
Tidskriftsartikel (refereegranskat)abstract
- Bi0.775La0.225O1.5 has been investigated by means of neutron scattering in combination with Rietveld refinement and reverse Monte Carlo (RMC) simulations to study the average and local atomic order of the material. At low temperature the crystallographic analysis shows a clear split of anionic positions similar to that reported for Sr doped bismuth oxides. Although this split appears to be absent in the average structure at high temperature, an even larger split of Bi-O local distances is found in the pair distribution function calculated from the RMC models. This latter feature can be indicative of a tendency to have similar oxygen environments for all Bi atoms at high temperature, as a precursor of the fluorite structure that is the stable phase at even higher temperatures. (c) 2005 Elsevier B.V. All rights reserved.
|
|
| 7. |
|
|
| 8. |
- Azad, A.K., et al.
(författare)
-
Structural and magnetic properties of LaFe0.5Cr0.5O3 studied by neutron diffraction, electron diffraction and magnetometry
- 2005
-
Ingår i: Materials Research Bulletin. - 0025-5408. ; 40(10), s. 1633-1644
-
Tidskriftsartikel (refereegranskat)abstract
- The structural and magnetic properties of the perovskite type compound LaFe0.5Cr0.5O3 have been studied by temperature dependent neutron powder diffraction and magnetization measurements. Rietveld refinement of the neutron diffraction data shows that the compound crystallizes in an orthorhombic perovskite structure with a random positioning of the Fe and Cr cations at the B sublattice. The magnetic structure at 10 K is a collinear antiferromagnetic one with the magnetic moment per site being equal to 2.79(4) mu(B). Magnetisation measurements confirm the overall antiferromagnetic behaviour. Moreover, it indicates a weak uncompensated magnetic moment close to the transition temperature T-N approximate to 265 K. This moment can be described by a magnetic cluster state, which remains up to 550 K. Electron diffraction patterns along with high-resolution transmission electron microscopy images reveal that the crystallites are composed by domains of different orientation, which share the same cubic perovskite sub-cell reflections. (C) 2005 Elsevier Ltd. All rights reserved
|
|
| 9. |
|
|
| 10. |
|
|
